index - Myopathies inflammatoires & thérapies innovantes ciblées Accéder directement au contenu

Dernières publications

Chiffres clés

121 Publications avec texte intégral

Open Access

53 %

Mots clés

COVID-19 Assisted communication devices Amyotrophy Aged Adjudication Multidisciplinarity Biopsy Auto-immunité Bioelectrical impedance analysis Abnormal movement Acute Kidney Injury/epidemiology/etiology Antisynthetase syndrome Adverse drug reactions Immune checkpoint inhibitors AAV humoral immunity DM Animals Anti‐mitochondrial antibodies Agalsidase Polymyositis Myocarditis CD8+ T-bet+ cells Middle Aged Systems biology Inclusion body myositis Cancer Deep immune profiling Interferon Anticorps anti-agalsidase Autoantibody Immunotherapy Myopathy Prognosis Adult Inborn errors of metabolism Aldosterone Anti-agalsidase antibodies Humans Antisynthétase Anti-interleukin-6 Skeletal muscle Outcome measures Case reports Adeno-associated vector Biomarkers Data integration Myositis Antiphospholipid syndrome Active AAV antibody Dependovirus/genetics/immunology Adeno-associated virus IBM Anti-MDA5 autoantibodies AAV Gene therapy Anémie hémolytique Idiopathic inflammatory myopathies Male Autoimmunity Analyses multidimensionnelles Interstitial lung disease Mass cytometry Autoimmune diseases CD8+T cells Amyotrophic lateral sclerosis Fabry disease Myositis and muscle disease Biomarker Anti-Mi2 AAV vectors Anticorps spécifique des myosites AAV vector Auto-antibodies Adeno-associated virus vector Aldostérone Antibodies Autoantibodies Muscle Arthritis Inflammation Adolescence Anti-drug antibodies Inflammatory myopathy Acid-alpha-glucosidase Antibody responses IMNM Cytokines Machine learning Auto‐antibodies Sphingosine-1-phosphate Biomarqueurs Female B cell homeostasis Antisynthetase Anti-IgE IgG Lysosomal storage diseases B-lymphocyte Anti-synthetase syndrome Dermatomyositis